Hims & Hers Health ( HIMS +1.45%) continues to be a volatile stock. The stock's value has been cut in half over the past year ...
Hims & Hers continues growing rapidly, but shrinking margins and rising costs are beginning to test the company's long-term ...
Zacks.com on MSN
DOCS vs. HIMS: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Info Systems sector have probably already heard of Doximity (DOCS) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best ...
Telehealth company Hims & Hers Health (NYSE:HIMS) fell short of the market’s revenue expectations in Q1 CY2026 as sales rose ...
May 11 (Reuters) - Hims & Hers Health raised its 2026 revenue forecast on Monday, betting on increased sales for its ...
Up 1 hour ago Live That wraps up our initial coverage of Hims and Hers Health’s Q1 results. Thank you for stopping by! Check ...
Hims & Hers reached a deal with Novo Nordisk in March to sell its GLP-1 weight loss drug Wegovy on its platform.
COPENHAGEN (Reuters) -Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging more ...
Hims & Hers Health (NYSE:HIMS) absorbed another analyst downgrade. Bank of America cut its price objective on Hims & Hers ...
Hims & Hers Health delivered a misunderstood Q1-26, raising FY-26 guidance and reaffirming 2030 revenue and EBITDA targets.
Shares of Hims & Hers Health fell 11% on Tuesday after the telehealth company's pivot to branded weight-loss drugs drove up ...
A bundled offering of Novo Nordisk’s FDA-approved Wegovy® on the Hims & Hers platform marks the first step in a long-term collaboration roadmap, pairing innovative treatments with a leading care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results